Published in Circulation on February 04, 2008
Macrophages in the pathogenesis of atherosclerosis. Cell (2011) 7.78
Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 4.52
Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation (2011) 1.79
A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res (2009) 1.72
Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest (2009) 1.62
Novel proteolytic microvesicles released from human macrophages after exposure to tobacco smoke. Am J Pathol (2013) 1.54
The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med (2008) 1.51
Transient collagen triple helix binding to a key metalloproteinase in invasion and development. Structure (2015) 1.45
Innate and adaptive immunity in atherosclerosis. Semin Immunopathol (2009) 1.40
Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol Int (2010) 1.29
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One (2011) 1.25
Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost (2009) 1.24
Membrane-type 1 matrix metalloproteinase regulates macrophage-dependent elastolytic activity and aneurysm formation in vivo. J Biol Chem (2008) 1.17
Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res (2008) 1.16
Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol (2008) 1.14
A membrane protease regulates energy production in macrophages by activating hypoxia-inducible factor-1 via a non-proteolytic mechanism. J Biol Chem (2010) 1.10
Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 1.05
Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am J Physiol Lung Cell Mol Physiol (2013) 1.02
The immunology of fibrosis: innate and adaptive responses. Trends Immunol (2010) 1.01
MT1-MMP regulates the PI3Kδ·Mi-2/NuRD-dependent control of macrophage immune function. Genes Dev (2012) 0.94
Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions. Cardiovasc Res (2010) 0.94
Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology (2014) 0.92
Deletion of the Mint3/Apba3 gene in mice abrogates macrophage functions and increases resistance to lipopolysaccharide-induced septic shock. J Biol Chem (2011) 0.89
MT1-MMP-dependent remodeling of cardiac extracellular matrix structure and function following myocardial infarction. Am J Pathol (2012) 0.89
Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability. Mediators Inflamm (2014) 0.87
Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. J Cardiovasc Pharmacol (2012) 0.87
Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model. Am J Physiol Heart Circ Physiol (2010) 0.86
Thin-capped atheromata with reduced collagen content in pigs develop in coronary arterial regions exposed to persistently low endothelial shear stress. Arterioscler Thromb Vasc Biol (2013) 0.85
Plaque rupture complications in murine atherosclerotic vein grafts can be prevented by TIMP-1 overexpression. PLoS One (2012) 0.83
Macrophages, dendritic cells, and regression of atherosclerosis. Front Physiol (2012) 0.82
TLR3 deficiency protects against collagen degradation and medial destruction in murine atherosclerotic plaques. Atherosclerosis (2013) 0.81
Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun (2016) 0.79
Differential effects of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 on atherosclerosis and monocyte/macrophage invasion. Cardiovasc Res (2015) 0.78
Macrophages in vascular inflammation and atherosclerosis. Pflugers Arch (2017) 0.76
Bone-marrow-derived matrix metalloproteinase-14: a novel target for plaque stability. Circulation (2008) 0.75
Atherosclerosis prevention in youth. Ann Vasc Dis (2012) 0.75
Nkx2-5 Is Expressed in Atherosclerotic Plaques and Attenuates Development of Atherosclerosis in Apolipoprotein E-Deficient Mice. J Am Heart Assoc (2016) 0.75
MEMBRANE TYPE 1-MATRIX METALLOPROTEINASE (MT1-MMP) IDENTIFIED AS A MULTIFUNCTIONAL REGULATOR OF VASCULAR RESPONSES. Fukushima J Med Sci (2015) 0.75
Plaque Size Is Decreased but M1 Macrophage Polarization and Rupture Related Metalloproteinase Expression Are Maintained after Deleting T-Bet in ApoE Null Mice. PLoS One (2016) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 11.51
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation (2007) 4.20
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol (2008) 4.20
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem (2008) 4.08
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 3.97
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J (2011) 3.93
The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature (2008) 3.93
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res (2002) 3.69
Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation (2006) 3.57
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52
Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation (2007) 3.51
Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res (2008) 3.47
Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A (2006) 3.38
Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol (2009) 3.09
Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (2006) 3.01
Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation (2006) 2.93
Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med (2012) 2.92
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. Am J Cardiol (2009) 2.91
Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol (2010) 2.90
Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol (2011) 2.83
Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation (2006) 2.68
Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res (2007) 2.66
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA (2012) 2.66
Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med (2002) 2.59
Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation (2006) 2.56
Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med (2007) 2.54
Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation (2008) 2.52
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.48
Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol (2004) 2.46
Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation (2011) 2.45
Molecular imaging of cardiovascular disease. Circulation (2007) 2.33
Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) (2006) 2.31
Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.28
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation (2003) 2.28
Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation (2004) 2.24
Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation (2007) 2.20
C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol (2006) 2.20
The American Journal of Cardiology and Journal of Periodontology editors' consensus: periodontitis and atherosclerotic cardiovascular disease. J Periodontol (2009) 2.20
ADAMTS metalloproteases generate active versican fragments that regulate interdigital web regression. Dev Cell (2009) 2.20
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging (2009) 2.17
Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. J Biol Chem (2003) 2.10
Adaptive immunity and atherosclerosis. Clin Immunol (2009) 2.08
Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation (2009) 2.07
Characterization of human atherosclerotic plaques by intravascular magnetic resonance imaging. Circulation (2005) 2.05
Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension (2006) 2.03
Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J Heart Valve Dis (2004) 2.02
Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation (2005) 2.01
Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest (2007) 2.00
Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol (2005) 1.98
Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation (2008) 1.97
Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA (2002) 1.95
Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med (2002) 1.91
Atherosclerosis and proteinase activation. Cardiovasc Res (2005) 1.88
MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. Dev Cell (2010) 1.87
Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood (2010) 1.86
Retracted Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res (2008) 1.85
Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.84
Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation (2009) 1.84